Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 15/20 | 0.79 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256628 | 1.00 | ADRB2 (0.79) | ADRB2ADRB3ADRB1SLC2A1ADRA1D | |
| SCHEMBL4259139 | 0.91 | ADRB2 (0.74) | ADRB2ADRB3ADRB1 | |
| SCHEMBL4259147 | 0.91 | ADRB2 (0.74) | ADRB2ADRB3ADRB1 | |
| SCHEMBL4255179 | 0.90 | ADRB2 (0.88) | ADRB2 | |
| SCHEMBL4255178 | 0.90 | ADRB2 (0.88) | ADRB2 | |
| SCHEMBL4256500 | 0.90 | ADRB2 (0.83) | ADRB2ADRB3ADRB1 | |
| SCHEMBL4256506 | 0.90 | ADRB2 (0.83) | ADRB2ADRB3ADRB1 | |
| SCHEMBL4260847 | 0.90 | ADRB2 (0.86) | ADRB2ADRB3ADRB1 | |
| SCHEMBL4260851 | 0.90 | ADRB2 (0.86) | ADRB2ADRB3ADRB1 | |
| SCHEMBL4260245 | 0.88 | ADRB2 (1.00) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1624868-B9 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2009-08-12 | — | — | EP | claimed |
| EP-1624868-B1 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2008-11-12 | — | — | EP | claimed |
| US-7268147-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2007-09-11 | — | — | US | claimed |
| US-20040229904-A1 | Compounds useful for the treatment of diseases | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| EP-1477167-A1 | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists | Pfizer Limited (GB) | 2004-11-17 | — | — | EP | claimed |
| EP-1624868-B9 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2009-08-12 | — | — | EP | disclosed |
| EP-1624868-B1 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-7268147-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1477167-A1 | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists | Pfizer Limited (GB) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229904-A1 | Compounds useful for the treatment of diseases | LTC4S, CYP11B1, CYP11B2 | ADRB2 901/4885ADRB3 802/4885ADRB1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.